|
| Status |
Public on Jan 01, 2017 |
| Title |
Non Responder - sample 26 |
| Sample type |
RNA |
| |
|
| Source name |
Pre Treatment biopsies
|
| Organism |
Homo sapiens |
| Characteristics |
tissue: CRC sample
disease state: Rectal cancer
name: PD_44
age: 63
Sex: Male
class: Non Responder
|
| Treatment protocol |
Pre CRT research biopsies (2-3 mm3) were collected during the initial diagnostic endoscopy, immediately frozen and stored in a liquid nitrogen tank.
|
| Growth protocol |
No growth protocols were used
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA was extracted by phenol/chloroform extraction (TRIzol; Invitrogen) prior to further purification by column chromatography (RNeasy Mini kit; Qiagen). RNA integrity was then assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies)
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 2 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).
|
| |
|
| Hybridization protocol |
Following fragmentation, 11 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Human Genome U133 Plus 2.0 Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450DX.
|
| Scan protocol |
GeneChips were scanned using the Scan GCS3000Dx.
|
| Description |
Gene expression data from CRC patients at diagnosis
|
| Data processing |
The data were normalized using R software [www.r-project.org] with BioConductor package [www.bioconductor.org] "affy" (RMA normalization).
|
| |
|
| Submission date |
Mar 21, 2013 |
| Last update date |
Jan 01, 2017 |
| Contact name |
Andrea Zangrando |
| E-mail(s) |
andrea.zangrando@unipd.it
|
| Organization name |
University of Padova
|
| Department |
Woman and Child's Health
|
| Lab |
Hemato-Oncology
|
| Street address |
Via Giustiniani, 3
|
| City |
Padova |
| ZIP/Postal code |
35138 |
| Country |
Italy |
| |
|
| Platform ID |
GPL570 |
| Series (1) |
| GSE45404 |
Integrative computational biology and molecular determinants of rectal cancer resistance to chemoradiotherapies |
|
